All articles tagged with #telmisartan
Dartmouth researchers find that the common blood pressure drug telmisartan can markedly enhance the cancer drug olaparib, boosting DNA damage and immune signaling to potentially extend PARP inhibitor benefits to more patients, with two clinical trials already launched in prostate and ovarian cancer.
University of Barcelona researchers found that pairing two approved drugs, pemafibrate and telmisartan, reversed liver fat in MASLD animal models and may reduce cardiovascular risk; the duo was effective at half-doses together, suggesting synergy and safer therapy. Telmisartan appears to upregulate PCK1, shifting metabolism away from lipid synthesis. Human trials are still needed.
A study in animal models suggests that a combination of two common heart medications, pemafibrate and telmisartan, may reverse fat accumulation in the liver, offering a potential new treatment for early-stage fatty liver disease (MASLD). However, further clinical research is needed before these drugs can be recommended for human treatment.
Researchers at the University of Barcelona found that the existing drugs pemafibrate and telmisartan, used separately and together, significantly reduce fat buildup in animal models of fatty liver disease, suggesting a potential new treatment approach, though human trials are still needed.
Researchers at the University of Barcelona have discovered that combining two existing drugs, pemafibrate and telmisartan, can significantly reduce liver fat accumulation and related cardiovascular risks in animal models of fatty liver disease, suggesting a potential new treatment approach, though human trials are still needed.